Large Cap · Healthcare · Drug Manufacturers - General
Large Cap · Healthcare · Drug Manufacturers - General
Get the AI take on PFE
Track it to unlock the price chart, verdict and what could change it.
Free to track. No card required.
Overall score
43/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Lowest
$25
Current price
$27.81
Median target
$28
Highest
$35.75
Forward P/E
Favorable · 52% below avg
9.67x
Price / sales
Strong · Priced modestly against the revenue it brings in
2.40x
Price / FCF
Strong · Priced well within what its cash flow supports
13.90x
EV / EBITDA
Strong · Operating earnings comfortably support this price
8.06x
ROIC
Reasonable · A middling return on the capital it puts to work
13.5%
ROE
Middle ground · Mixed
5.0%
Debt / equity
Favorable · 0.72 - solid leverage
0.74x
Current ratio
Reasonable · Just enough on hand to cover near-term bills
1.27x
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $152.69B | 35.5 | -0.2% | 43 | |
| $11.53B | 22.0 | +19.7% | 78 | |
| $4.60B | 13.9 | +13.5% | 77 | |
| $33.87B | 35.4 | +15.5% | 77 | |
| $1.11T | 40.1 | +49.6% | 76 |
Shopify attracts a new bull as Rosenblatt launches coverage
MixedWhich Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
MixedNotable Wednesday Option Activity: EL, PFE, NOW
MixedPre-Market Most Active for Aug 19, 2026 : CAST, MRNA, SKDD, SKHY, SKUU, MUU, NOK, MRK, STLA, LYG, NIO, PFE
Mixed